CA
ZNTL icon

Clearstead Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Clearstead Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,115
Closed -$1.68K – 3300
2025
Q3 		$1.68K Sell
1,115
-946
-46% -$1.42K ﹤0.01% 2502
2025
Q2 		$2.39K Buy
+2,061
New +$2.72K ﹤0.01% 2287

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Clearstead Advisors's ZNTL Position: Q4 2025 in Review

Clearstead Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 1,115 shares — an estimated $1.68K sold.

Clearstead Advisors first reported a position in ZNTL in Q2 2025 and held it in 2 quarters. The position peaked at $2.39K in Q2 2025. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

  • Clearstead Advisors reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Clearstead Advisors sold 1,115 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $1.68K.
  • Clearstead Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Clearstead Advisors's Zentalis Pharmaceuticals position peaked at $2.39K in Q2 2025.
  • 86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.